Association of recombinant human growth hormone replacement with improved arterial oxygenation in patients with hepatopulmonary syndrome secondary to hypopituitarism: a retrospective case series

Objective This retrospective single-arm case series described the changes in arterial oxygenation in patients with hepatopulmonary syndrome (HPS) secondary to hypopituitarism who received recombinant human growth hormone (rhGH) replacement. Methods A total of 21 patients were enrolled, with etiologies including pituitary stalk interruption syndrome (n = 3), post-resection craniopharyngioma (n = 11), and sellar germ cell tumors (n = 7). The median interval from hypopituitarism diagnosis to HPS onset was 9 years. Ten patients received rhGH therapy. The 11 non-GH patients served as a baseline descriptive comparison; follow-up oxygenation data were available for only 3, precluding longitudinal between-group comparison. Results Among the ten treated patients, rhGH therapy was associated with average improvement in PO 2 (from 48.6 ± 4.2 mmHg to 91.0 ± 6.0 mmHg; P = 0.0006) and average reductions in P(A–a)O 2 (from 60.8 ± 4.8 mmHg to 12.2 ± 5.5 mmHg; P < 0.0001). Eight of ten treated patients maintained normal PO 2 levels during extended therapy lasting 8 to 84 months, while two showed partial improvement without reaching the normal threshold (41→57 mmHg and 46→61 mmHg). In three patients with available data, liver stiffness measurement decreased significantly after 7 to 13 months of rhGH treatment (from 33.0 ± 7.6 kPa to 24.7 ± 6.4 kPa). Given the small number of patients (n = 3), these data are presented descriptively only. Conclusion rhGH replacement was associated with significantly improved oxygenation and sustained therapeutic benefits in patients with hypopituitarism-associated HPS, supporting further investigation of its potential as an adjunctive therapy; however, randomized controlled studies are needed.

Authors

Institutions

Publication Details

Journal
Frontiers in Endocrinology
Published
2026-11-17
DOI
https://doi.org/10.3389/fendo.2026.1977951
Primary Topic
Growth Hormone and Insulin-like Growth Factors
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Association of recombinant human growth hormone replacement with improved arterial oxygenation in patients with hepatopulmonary syndrome secondary to hypopituitarism: a retrospective case series

Min Nie, 马海陆, Jiangfeng Mao, Qin Han et al.
1 links
Frontiers in Endocrinology
Growth Hormone and Insulin-like Growth Factors
article

Association of recombinant human growth hormone replacement with improved arterial oxygenation in patients with hepatopulmonary syndrome secondary to hypopituitarism: a retrospective case series

Min Nie, 马海陆, Jiangfeng Mao, Qin Han, Xueyan Wu, Hongying Liu, Xi Wang
article en

Abstract

Objective This retrospective single-arm case series described the changes in arterial oxygenation in patients with hepatopulmonary syndrome (HPS) secondary to hypopituitarism who received recombinant human growth hormone (rhGH) replacement. Methods A total of 21 patients were enrolled, with etiologies including pituitary stalk interruption syndrome (n = 3), post-resection craniopharyngioma (n = 11), and sellar germ cell tumors (n = 7). The median interval from hypopituitarism diagnosis to HPS onset was 9 years. Ten patients received rhGH therapy. The 11 non-GH patients served as a baseline descriptive comparison; follow-up oxygenation data were available for only 3, precluding longitudinal between-group comparison. Results Among the ten treated patients, rhGH therapy was associated with average improvement in PO 2 (from 48.6 ± 4.2 mmHg to 91.0 ± 6.0 mmHg; P = 0.0006) and average reductions in P(A–a)O 2 (from 60.8 ± 4.8 mmHg to 12.2 ± 5.5 mmHg; P < 0.0001). Eight of ten treated patients maintained normal PO 2 levels during extended therapy lasting 8 to 84 months, while two showed partial improvement without reaching the normal threshold (41→57 mmHg and 46→61 mmHg). In three patients with available data, liver stiffness measurement decreased significantly after 7 to 13 months of rhGH treatment (from 33.0 ± 7.6 kPa to 24.7 ± 6.4 kPa). Given the small number of patients (n = 3), these data are presented descriptively only. Conclusion rhGH replacement was associated with significantly improved oxygenation and sustained therapeutic benefits in patients with hypopituitarism-associated HPS, supporting further investigation of its potential as an adjunctive therapy; however, randomized controlled studies are needed.

Frontiers in EndocrinologyVol. 17
Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Peking Union Medical College Hospital (CN), Institute of Basic Medical Sciences of the Chinese Academy of Medical Sciences (CN)
Good health and well-being
Growth Hormone and Insulin-like Growth Factors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon